CYRX · Cryoport, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA from continuing operations non-GAAP | $0.4M | Q2 2026 | — |
| Americas clinical trials supported | 579 | as of June 30, 2026 | — |
| APAC clinical trials supported | 55 | as of June 30, 2026 | — |
| Commercially approved cell and gene therapies supported | 22 | Q2 2026 | — |
| EMEA clinical trials supported | 145 | as of June 30, 2026 | — |
| Global clinical trials supported | 779 | Q2 2026 | — |
|
|
|||
| Phase 1 clinical trials supported | 316 | as of June 30, 2026 | — |
| Phase 2 clinical trials supported | 369 | as of June 30, 2026 | — |
| Phase 3 clinical trials supported | 94 | as of June 30, 2026 | — |
| Year-over-year improvement in adjusted EBITDA from continuing operations non-GAAP | $2.2M | Q1 2026 | — |
| Commercially approved therapies supported | 20 | Year ended December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Integrated Freight & Logistics — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CYRX
this stock
Cryoport, Inc.
|
$772.40M | +58.9% | +12.4% | — | 4.9% |
|
UPS
United Parcel Service Inc
|
$88.91B | +5.4% | +8.2% | — | 2.8% |
|
FDX
Fedex Corp
|
$79.17B | — | +8.5% | — | 2.1% |
|
JBHT
Hunt J B Transport Services Inc
|
$26.27B | +43.9% | +9.7% | 39.7 | 2.9% |
|
EXPD
Expeditors International Of Washington Inc
|
$24.19B | +24.9% | +13.5% | 27.1 | 3.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CYRX | +0.9% | -7.6% | +87.4% | +1.1% | +58.9% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +0.5% | -12.1% | +73.6% | -2.9% | +45.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.